Amneal Pharmaceuticals Inc. logo

Amneal Pharmaceuticals Inc.

AMRX | NASDAQ
Chart Builder DCF Calculator
$19.51
-$0.65 (-3.22%)
Sep 22, 2026, 10:36 AM ET · Market open

Market Data

Market Cap
$6.44B
Enterprise Value
$9.1B
Beta
1.24
Average Volume
1.89M
Shares Outstanding (Diluted)
328.1M
Shares Change YoY
1.78%
Institutional Ownership
50.91%
Exchange
NASDAQ
ISIN
US03168L1052

Price Performance

Price Change 1M
12.9%
Price Change 3M
21.0%
Price Change 6M
64.4%
Price Change YTD
59.2%
Price Change 1Y
101.6%
Price Change 3Y
381.1%
Price Change 5Y
279.7%
1M CAGR (ann.)
11.1%
1Y CAGR (ann.)
105.5%
5Y CAGR (ann.)
31.6%
All-Time CAGR
8.5%

Valuation

PE Ratio
41.14
Forward PE
16.65
PEG Ratio
0.01
Forward PEG
2.36
PS Ratio
2.06
Forward PS
1.90
PB Ratio
194.94
P/FCF Ratio
43.51
P/Adj. FCF Ratio
53.14
P/OCF Ratio
32.00
EV/Sales
2.92
EV/EBIT
30.08
EV/EBITDA
20.33
EV/FCF
61.52
Earnings Yield
2.4%
FCF Yield
2.3%
Adj. FCF Yield
1.9%

Financial Health

Net Debt
$2.54B
Total Debt
$2.79B
Cash & Short-Term Investments
$127.64M
Total Assets
$3.78B
Current Ratio
2.20
Quick Ratio
1.44
Debt / Equity Ratio
84.54
Debt / EBITDA
6.23
Debt / FCF
18.87
OCF / Debt
0.08
Interest Coverage
1.77
Altman Z-Score
2.46
Piotroski F-Score
6

Margins & Profitability

Gross Profit Margin
39.3%
Operating Profit Margin
7.9%
EBITDA Margin
20.9%
Net Profit Margin
5.0%
FCF Margin
4.8%
Adj. FCF Margin
3.9%
SBC / Revenue
0.9%
SBC Impact (per share)
-18.1%

Returns

Return on Assets
4.2%
Return on Equity
-326.8%
Return on Invested Capital
13.4%
Return on Capital Employed
13.9%
Return on Tangible Assets
6.1%

Historical Growth (CAGR)

Revenue CAGR 3Y
10.5%
Revenue CAGR 5Y
8.7%
Revenue CAGR 10Y
13.3%
EPS CAGR 3Y
1349.3%
EPS CAGR 5Y
52.9%
EPS CAGR 10Y
-13.1%
FCF CAGR 3Y
0.5%
FCF CAGR 5Y
-4.0%
FCF CAGR 10Y
16.7%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
17
EPS Growth Next 3Y
55.1%
Revenue Growth Next 3Y
12.2%
Earnings Date
Oct 28, 2026
EPS Estimate (next Q)
$0.23
EPS Growth Est (next Q)
35.3%
Revenue Est (next Q)
$812.86M
Revenue Growth Est (next Q)
3.6%

Fair Value Estimates

Graham Number
$2.02
Graham Upside
-90.0%
Lynch Fair Value
$12.25
Lynch Upside
-39.2%
Price Target
$22.25
Price Target Upside
10.4%

Cash Flow

Operating Cash Flow
$220.04M
Free Cash Flow
$147.96M
Adj. Free Cash Flow
$121.15M
FCF Per Share
$0.26
OCF Per Share
$0.63
OCF/S Ratio
6.4%

Income Statement

Revenue
$3.12B
Gross Profit
$1.23B
Operating Income
$246.62M
EBITDA
$447.79M
Net Income
$157.6M
EPS (Diluted)
$0.49
Revenue / Employee
$358.34K
Profit / Employee
$18.12K
Employees
8,700

© 2026 bestshares.com. All rights reserved.